
Roivant’s CEO thinks China is a ‘red herring’
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring.
In this week’s episode of "The Top Line," Fierce Biotech’s Darren Incorvaia chats with Gline about China, artificial intelligence and the exciting year ahead for Roivant’s lead asset brepocitinib.
To learn more about the topics in this episode:
After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
NIH grant cuts hit…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.